Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 – PRISM MediaWire – Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined […]
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported […]
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy Longevity New York, NY, September 17, 2024 – PRISM MediaWire – The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will […]
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet […]
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth. Characterized by symptoms such as burning pain, […]
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
Pittsburgh, PA, August 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024. LP-20, which […]
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
New York, NY. August 21, 2024 – ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke(“TTS”)regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering […]
ANEW MEDICAL, INC. Appoints New CFO
New York, NY, August 19, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company’s Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was […]
ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS
New York, NY, August 8, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative diseases […]
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu […]